Phase 4 Schizophrenia Trial, Recruiting NCT07221877 Sponsor: Bristol-Myers Squibb Condition: Schizophrenia
Back to Schizophrenia

Phase 4 Schizophrenia Trial, Recruiting

NCT07221877
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years old, both male and female, who have been diagnosed with schizophrenia confirmed through a psychiatric evaluation using standard diagnostic tools (DSM-5 and MINI assessment)
  • People whose schizophrenia symptoms are rated as moderate or below on standard clinical rating scales (PANSS total score of 80 or under, and CGI-S score of 4 or under) at both the screening and baseline appointments
  • People whose body weight falls within a healthy to moderately obese range (BMI between 18 and 40)
  • People who are willing and able to stop taking all antipsychotic medications before the baseline visit, and who are able to follow the requirements of the study

Who may not be able to join:

  • People who have been newly diagnosed with schizophrenia, or who have been diagnosed with any other DSM-5 mental health condition within the past 12 months
  • People who have had an alcohol or drug use disorder within the past 12 months
  • People with a significant medical condition or disorder that could affect their safety or the reliability of the study results
  • People considered to be at risk of suicidal behaviour
  • People who are pregnant or breastfeeding
  • There may be additional criteria not listed here that the trial site will assess

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
20 January 2026
Est. completion
30 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in voiding dynamics (Qmax) over time; Change from baseline in post-void residual volume (PVR) over time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov